Brief: Revance Therapeutics Q4 product revenue USD 45.73 million
28/02/2023 21:13
Feb 28 (Reuters) - Revance Therapeutics Q4 product revenue USD 45.73 million. * Q4 net income USD -145.952 million * Q4 EPS USD -1.82 * Q4 operating expenses USD 194.332 million * Q4 service revenue USD 2.944 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup